Acromegaly Market Analysis 2034 - Market Size, Medication and Companies by DelveInsight

(Albany, USA) DelveInsight's report, "Acromegaly Market Insights, Epidemiology, and Market Forecast-2034," offers a comprehensive analysis of Acromegaly, covering its historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The study presents detailed insights into current treatment approaches, emerging therapies, and the market share of individual drugs. It also provides market size estimates for Acromegaly from 2020 to 2034, segmented across the seven major markets. Additionally, the report outlines treatment algorithms, key market drivers and challenges, and the prevailing unmet medical needs, helping identify the most promising growth opportunities while evaluating the untapped potential of the Acromegaly market.

Request for a Free Sample Report @ Acromegaly Market Forecast - https://www.delveinsight.com/report-store/acromegaly-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Acromegaly Market Report are:
• Acromegaly market size was valued ~USD 1,300 million in 2023 and is to grow with a significant CAGR during the study period (2020-2034)
• Leading Acromegaly companies working in the market are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.
• Key Acromegaly Therapies expected to launch in the market are Paltusotine (CRN 00808), CAM-2029 (octreotide subcutaneous depot), and many others.
• In July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly.
• In March 2025, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation (ODD) for the treatment of acromegaly.
• In January 2025, MAR002 is a promising first-in-class antibody targeting the growth hormone receptor (GHR), being developed for the treatment of acromegaly. Acromegaly is a serious, life-threatening condition primarily driven by insulin resistance, lipotoxicity, and cardiovascular issues. Current treatments for acromegaly often fail to provide optimal disease management. In the U.S., it is estimated that over 30,000 individuals are affected by acromegaly.
• In December 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist available for adults living with acromegaly.
• In October 2024, Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly.
• In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.
• In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.
• In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.
• In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.
• In September 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today revealed that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist being developed for the proposed treatment and long-term maintenance therapy of acromegaly.
• In 2023, somatostatin therapies generated the largest market size among all acromegaly treatments in the United States, reaching around USD 500 million, followed by growth hormone antagonists at approximately USD 160 million.
• In 2023, somatostatin therapies generated the highest revenue among all treatments in the EU4 and the UK, totaling approximately USD 300 million, followed by growth hormone antagonists at around USD 90 million.
• In the EU4 countries and the UK, the UK accounted for the largest share of the acromegaly market, contributing around 30% of the total market size in these regions.

Acromegaly Overview
Acromegaly is a rare hormonal disorder that results from the excessive production of growth hormone (GH), typically caused by a benign tumor on the pituitary gland known as a pituitary adenoma. This overproduction of GH leads to increased levels of insulin-like growth factor 1 (IGF-1), which causes abnormal growth of bones and tissues over time. Acromegaly usually develops gradually and often goes undiagnosed for years due to its slow progression.

Common symptoms of acromegaly include enlarged hands and feet, facial changes (such as protruding jaw and enlarged nose), joint pain, thickened skin, fatigue, and excessive sweating. If left untreated, acromegaly can lead to serious complications like hypertension, type 2 diabetes, cardiomyopathy, sleep apnea, and an increased risk of colon polyps or cancer.

Acromegaly Diagnosis involves measuring GH and IGF-1 levels in the blood, along with MRI scans to detect pituitary tumors. Acromegaly Treatment options include surgical removal of the tumor, medications to reduce GH production (such as somatostatin analogs or GH receptor antagonists), and radiation therapy when surgery isn't feasible. Early diagnosis and management of acromegaly are essential to prevent complications, improve quality of life, and reduce mortality risk associated with the disease.

Do you know what will be the Acromegaly market share in 7MM by 2034 @ Acromegaly Treatment Market - https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acromegaly Market Outlook
In 2023, the Acromegaly market across the 7MM was valued at approximately USD 1,300 million, with the US accounting for ~55% of the total market. Among therapies, somatostatin analogs generated the highest revenue (~USD 300 million), followed by growth hormone antagonists (~USD 90 million in EU4 and the UK). Acromegaly is a rare hormonal disorder caused by excessive growth hormone (GH) production, typically due to a benign pituitary adenoma. It mainly affects adults aged 30-50 but can occur at any age.

Symptoms include progressive enlargement of facial features, hands, and feet, along with internal organ involvement, which may lead to cardiovascular and respiratory complications. Joint pain, arthritis, and carpal tunnel syndrome are also common. Diagnosis involves GH and IGF-1 blood tests and imaging to detect pituitary tumors. In 2023, there were about 60,000 diagnosed prevalent cases in the 7MM, with females slightly more affected (~14,000 cases).

Treatment options include surgery, radiation, and medications to control GH production. Early intervention can reverse some symptoms, though long-standing changes may be permanent. Ongoing research includes therapies like Crinetics' Paltusotine and Camurus' CAM2029. Long-term follow-up is essential to manage hormone levels and associated complications.

The acromegaly market is driven by increasing disease awareness, improved diagnostic techniques, and advancements in treatment options, including novel somatostatin analogs, growth hormone receptor antagonists, and combination therapies. Rising healthcare expenditure, supportive reimbursement policies, and ongoing research into targeted therapies further boost market growth. Additionally, growing clinical trial activity and strategic collaborations among pharmaceutical companies enhance treatment accessibility and innovation.

However, market growth faces barriers such as the rarity of the disease, leading to delayed diagnosis and limited patient pools, which hinder large-scale clinical studies. High treatment costs and the need for lifelong therapy can limit access, particularly in low- and middle-income regions. Adverse effects of current drugs, resistance to treatment, and the complexity of managing associated comorbidities also challenge patient compliance. Furthermore, limited awareness in developing regions and the absence of curative therapies restrict the overall market potential.

Acromegaly Epidemiology
The Acromegaly epidemiology section provides insights into the historical and current Acromegaly patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acromegaly market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acromegaly diagnosed prevalence pool? Download report @ Acromegaly Prevalence - https://www.delveinsight.com/report-store/acromegaly-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acromegaly Drugs Uptake
This section focuses on the uptake rate of the potential Acromegaly drugs recently launched in the Acromegaly market or expected to be launched in 2020-2034. The analysis covers the Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acromegaly Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acromegaly market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acromegaly Pipeline Development Activities
The Acromegaly report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acromegaly key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acromegaly market share by 2034? Click here @ Acromegaly Therapeutics Market - https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acromegaly Therapeutics Assessment
Major key companies are working proactively in the Acromegaly Therapeutics market to develop novel therapies which will drive the Acromegaly treatment markets in the upcoming years are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.

Acromegaly Report Key Insights
1. Acromegaly Patient Population
2. Acromegaly Market Size and Trends
3. Key Cross Competition in the Acromegaly Market
4. Acromegaly Market Dynamics (Key Drivers and Barriers)
5. Acromegaly Market Opportunities
6. Acromegaly Therapeutic Approaches
7. Acromegaly Pipeline Analysis
8. Acromegaly Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Acromegaly Market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.